Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 6 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,541 followers.

New research: Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands: Background The phase 3 clinical trial KEYNOTE-426 suggested a higher… #oncology htt

08 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.